SRR8943004
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.630
- INTERFERON_GAMMA_RESPONSE+0.540
- IL6_JAK_STAT3_SIGNALING+0.490
- ALLOGRAFT_REJECTION+0.460
- TNFA_SIGNALING_VIA_NFKB+0.430
- INFLAMMATORY_RESPONSE+0.410
- P53_PATHWAY+0.280
- TGF_BETA_SIGNALING+0.280
- COMPLEMENT+0.240
- COAGULATION+0.210
Top 10 suppressed
- E2F_TARGETS-0.640
- MYC_TARGETS_V2-0.550
- G2M_CHECKPOINT-0.540
- CHOLESTEROL_HOMEOSTASIS-0.450
- MYC_TARGETS_V1-0.450
- MTORC1_SIGNALING-0.350
- MITOTIC_SPINDLE-0.340
- UNFOLDED_PROTEIN_RESPONSE-0.340
- PEROXISOME-0.270
- FATTY_ACID_METABOLISM-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | GSM5359418 | — | — | 0.894 |
| 2 | TCGA-OR-A5LK-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Oncocytic Type | 0.886 |
| 3 | BS_CS170P7T | pilocytic astrocytoma | — | 0.869 |
| 4 | TCGA-67-6216-01A-11R-1755-07 | — | cohortA1 | 0.862 |
| 5 | SRR8518166 | — | D | 0.858 |
| 6 | DRR168509 | — | — | 0.855 |
| 7 | 20030005.Her2HRpos | — | A | 0.855 |
| 8 | SRR8518288 | — | A | 0.852 |
| 9 | 98e49cc4-1040-4291-b975-da3e8fc3ddfc | — | — | 0.852 |
| 10 | MUTZ3_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.630 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.540 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.490 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.280 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |
| APOPTOSIS | 0.030 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.020 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |